Across TCGA pan-cancer cohorts, SLC18A3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC18A3 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SLC18A3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC18A3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, CESC, and HNSC are the cancer types where SLC18A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.948	0.429	.006	28	view →
CESC	OS	Median	II,III,IV	0.156	0.759	.007	24	view →
HNSC	OS	Median	All	0.251	0.717	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	DFS	Median	All	0.242	0.537	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SLC18A3 tumor-vs-normal RNA expression · all SLC18A3 data types